Translational research on HGF: A phase I/II study of recombinant human HGF for the treatment of fulminant hepatic failure.
Hepatocyte growth factor (HGF) is a potential therapeutic agent for fatal liver diseases, including fulminant hepatic failure (FHF). After performing a number of preclinical tests with recombinant human HGF (rh-HGF), we started a phase I/II study in September 2005 of patients with FHF or late-onset hepatic failure (LOHF), to examine the safety and clinical efficacy of rh-HGF. We first administered rh-HGF (0.6 mg/m(2)/day) for 13 days to a 67-year-old Japanese man with FHF. All data from this patient were reviewed by the independent data monitoring committee, and the safety of rh-HGF was recognized. Finally, a clinical trial of rh-HGF was approved to be continued. As of August 2007, we have administered rh-HGF to four patients with FHF or LOHF. All patients showed a moderate decrease in systolic blood pressure during rh-HGF administration, while the urinary excretion of albumin did not increase in all cases. In the first and third patients, hepatic failure gradually progressed, and they died 66 and 29 days, respectively, after encephalopathy occurred. The second and fourth patients are presently still alive. In conclusion, we started a clinical trial that examined the effects of rh-HGF in patients with FHF or LOHF, and in the four patients with FHF or LOHF enrolled in this study, repeated doses of rh-HGF did not produce any severe side effects.
Ido
Akio
A
Digestive and Life-style Related Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Moriuchi
Akihiro
A
Marusawa
Hiroyuki
H
Ikeda
Kazuki
K
Numata
Masatsugu
M
Yamaji
Naohisa
N
Setoyama
Hitoshi
H
Ida
Hiroshi
H
Oketani
Makoto
M
Chiba
Tsutomu
T
Tsubouchi
Hirohito
H